Patents by Inventor Gary Stuart Tilbrook

Gary Stuart Tilbrook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961250
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: March 30, 2021
    Assignee: PAION UK LIMITED
    Inventors: Gary Stuart Tilbrook, Louisa Jane Quegan
  • Publication number: 20200316088
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in Ft dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 8, 2020
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Patent number: 10722522
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: July 28, 2020
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Publication number: 20200171046
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: June 28, 2019
    Publication date: June 4, 2020
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Publication number: 20200039990
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 6, 2020
    Applicant: PAION UK LIMITED
    Inventors: Gary Stuart TILBROOK, Louisa Jane QUEGAN
  • Patent number: 10472365
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: November 12, 2019
    Assignee: PAION UK LIMITED
    Inventors: Gary Stuart Tilbrook, Louisa Jane Quegan
  • Patent number: 10342800
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 9, 2019
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Publication number: 20190111062
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: December 7, 2018
    Publication date: April 18, 2019
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Patent number: 10195210
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: February 5, 2019
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Publication number: 20180318316
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 8, 2018
    Applicant: PAION UK LIMITED
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Patent number: 10052334
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 21, 2018
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Publication number: 20180186803
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 5, 2018
    Applicant: PAION UK LIMITED
    Inventors: Gary Stuart Tilbrook, Louisa Jane Quegan
  • Patent number: 10000464
    Abstract: The invention concerns a new process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-4-yl]-propionic acid methyl ester or 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-4-yl]propionic acid methyl ester benzene sulfonate (P) which comprises reacting 3-[(S)-7-bromo-2-((R and/or S)-2-hydroxy-propylamino)-5-pyridin-2-yl-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester of formula (EM) with an oxidizing agent and optionally treating the reaction product under acidic conditions, such as to produce the compound of formula (F) or the compound (P), and new compounds useful as starting materials or as intermediates for performing that process.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: June 19, 2018
    Assignee: PAION UK LIMITED
    Inventors: Gary Stuart Tilbrook, Andreas Schumacher, Rene Emmenegger
  • Patent number: 9914738
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 13, 2018
    Assignee: PAION UK LIMITED
    Inventors: Gary Stuart Tilbrook, Louisa Jane Quegan
  • Publication number: 20180042939
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 15, 2018
    Applicant: Paion UK Limited
    Inventors: Karin WILHELM-OGUNBIYI, Keith BORKETT, Gary Stuart TILBROOK, Hugh WILTSHIRE
  • Publication number: 20180002338
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Applicant: Paion UK Limited
    Inventors: Gary Stuart TILBROOK, Louisa Jane Quegan
  • Patent number: 9827251
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: November 28, 2017
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Patent number: 9777007
    Abstract: The invention relates to besylate salts of the compound of formula (I): Methods of preparing the salts, and their use as medicaments, in particular for sedative or hypnotic, anxiolytic, muscle relaxant, or anticonvulsant purposes is also described.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 3, 2017
    Assignee: PAION UK LIMITED
    Inventors: Gary Stuart Tilbrook, Louisa Jane Quegan
  • Patent number: 9737547
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 22, 2017
    Assignee: PAION UK LIMITED
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Publication number: 20170112852
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Inventors: Karin WILHELM-OGUNBIYI, Keith BORKETT, Gary Stuart TILBROOK, Hugh WILTSHIRE